Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · FRACTYL HEALTH, INC. (GUTS)

Fractyl Health to cut 45% of workforce, discontinue Rejuva gene therapy program

Mixed Impact 4 of 5 restructuring Written later

Fractyl Health is reducing its workforce by about 45% to concentrate resources on its Revita program, and it will stop internal development of its Rejuva gene therapy program while it seeks strategic alternatives for that program. The company expects about $2 million in severance and related charges, mostly in the fourth quarter of 2026, and says its cash should last into the second quarter of 2027, with quarterly cash burn expected to fall about 50% to roughly $8 million by the end of that quarter.

Key points

  • Workforce reduction of approximately 45% of current headcount, expected to be substantially completed by November 2026
  • Severance and employee termination charges estimated at about $2 million, mostly in Q4 2026; other charges possible but not yet estimated
  • Jay Caplan retires as President and Chief Product Officer effective October 30, 2026; CEO Harith Rajagopalan appointed President
  • Cash runway extended into Q2 2027; quarterly operating cash burn expected to fall about 50% to roughly $8 million by end of Q2 2027

The filing

CompanyFRACTYL HEALTH, INC. (GUTS)
Form8-K, current report
Filed with the SECOct 22, 2026, 7:01 AM ET
Accession number0001193125-26-428302

Items reported: 2.05 Exit / Restructuring Costs5.02 Director / Officer Change8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.